Covariates | Univariate analysis | Multivariate analysis cox regression of survival | ||||||
---|---|---|---|---|---|---|---|---|
MBC | Entire cohort | MBC | Entire cohort | |||||
Χ 2 | P | Χ 2 | P | RR (95% CI) | P | RR (95% CI) | P | |
Age ≤50 years | <0.001 | 0.998 | 0.47 | 0.490 | 1.32 (0.38 to 4.56) | 0.666 | 1.39 (0.91 to 2.12) | 0.129 |
Tumor size ≥2 cm | 0.62 | 0.432 | 25.35 | <0.001 | 0.42 (0.08 to 2.31) | 0.320 | 2.71 (1.39 to 5.28) | 0.003 |
Node-positive | 2.34 | 0.127 | 99.36 | <0.001 | 0.74 (0.16 to 3.53) | 0.710 | 2.40 (1.42 to 4.07) | 0.001 |
Higher TNM stage | 4.53 | 0.031 | 95.60 | <0.001 | 7.84 (0.76 to 80.54) | 0.083 | 2.19 (1.33 to 3.62) | 0.002 |
ER-positive | 0.14 | 0.706 | 0.57 | 0.184 | 1.15 (0.34 to 3.98) | 0.817 | 0.92 (0.58 to 1.44) | 0.697 |
PR-positive | 0.04 | 0.847 | 0.38 | 0.103 | 1.06 (0.28 to 3.92) | 0.936 | 0.80 (0.52 to 1.24) | 0.321 |
HER2/neu-positive | 1.70 | 0.193 | 8.29 | 0.004 | 1.31 (0.37 to 4.69) | 0.677 | 1.31 (0.86 to 2.00) | 0.204 |
Chemotherapy | 1.02 | 0.314 | 0.89 | 0.345 | 0.37 (0.07 to 2.01) | 0.251 | 0.60 (0.30 to 1.20) | 0.151 |
Radiotherapy | 7.75 | 0.005 | 96.42 | <0.001 | 0.13 (0.03 to 0.71) | 0.015 | 1.81 (1.22 to 2.92) | 0.015 |
Hormonotherapy | 0.13 | 0.722 | 18.70 | <0.001 | 0.50 (0.13 to 1.93) | 0.317 | 0.69 (0.43 to 1.01) | 0.122 |